Longevity Report · Week of August 15, 2026
Peptide regulation, GLP-1 cost realities, brain-aging inflection, active-sleep metabolism, and a metabolic longevity gene
- FDA Compounding Committee Advances Six Peptides — But That Is Not Approval"When you write a script for TB-500, what form do you think your patients are getting? Does anyone know? I certainly don't."
- GLP-1 Reality Check: Heart Failure Signal Strengthens While Oral Agents Match ThemArticle — "GLP-1 Reality Check: Heart Failure Signal Strengthens While Oral Agents Match Them for Diabetes": Article — "GLP-1 Reality Check: Heart Failure Signal Strengthens While Oral Agents Match Them for Diabetes": Tw…
- Brain Aging Reconsidered: Midlife Inflection Point Replaces the Linear-Decline ModelHere is the thing most people believe about the aging brain: that it slides. That from your twenties onward the tissue thins a little each year, memory fades on a gentle grade, and by seventy you are simply further down …
- Sleep as Active Metabolism: A Deep-Sleep Brain Circuit Linked to Fat Loss and Recovery"No hacks. No injections. Just the elegant power of sleep, doing exactly what it was designed to do." That is how SuperAge closes its account of the UC Berkeley study, framing your deepest sleep cycles as "your body's bu…
- Million-Person Study Flags Rare FNIP1 Variants as a Cardiometabolic Protective GeneAbout 1 in 7,000 people carry a mutation that quietly disables one copy of a gene called FNIP1, and without doing anything at all — no diet, no drug — they run leaner livers, better blood sugar, and roughly 60% lower odd…
Threads we are following
- Whether the FDA formally accepts the PCAC recommendation and initiates notice-and-comment rulemaking
- Whether head-to-head randomized trials, not observational emulations, will confirm SGLT-2i superiority over GLP-1RAs for heart-failure and renal endpoints
- Whether the contradictory CHIP-mutation findings (amyloid clearance vs. pro-inflammatory microglia) get resolved by a follow-up study
- Whether an intervention trial will test if increasing slow-wave sleep in humans actually reduces fat mass and raises lean mass.
- Whether pharmacologic FNIP1 inhibition can reproduce carrier-level protection in humans without needing paralogue suppression
One issue a week. Free.
sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.